Developmental haemostasis: Secondary haemostasis

Seminars in Fetal and Neonatal Medicine

Volumn 16, Issue 6, 2011, Pages 294-300

  Monagle, Paul ^a,b,c   Massicotte, Patricia ^d  

^a ROYAL CHILDREN'S HOSPITAL   (Australia)

^b UNIVERSITY OF MELBOURNE   (Australia)

^c MURDOCH CHILDREN'S RESEARCH INSTITUTE   (Australia)

^d UNIVERSITY OF ALBERTA   (Canada)

Author keywords

Coagulation; Fetus; Haemostasis; Neonate

Indexed keywords

PLASMA PROTEIN;

ADULT; CHILD; DEVELOPMENTAL DISORDER; EMBRYO; FETUS; HEMOSTASIS; HUMAN; NEWBORN; QUALITATIVE ANALYSIS; QUANTITATIVE ANALYSIS; REVIEW;

BLOOD COAGULATION; BLOOD COAGULATION FACTORS; BLOOD COAGULATION TESTS; FETAL DEVELOPMENT; FETUS; HEMOSTASIS; HUMANS; INFANT, NEWBORN;

EID: 80053591749     PISSN: 1744165X     EISSN: 18780946     Source Type: Journal    
DOI: 10.1016/j.siny.2011.07.007     Document Type: Review

References (110)

1. Bleyer W.A., Hakami N., Shepard T.H. The development of hemostasis in the human fetus and newborn infant. J Pediatr 1971, 79:838-853.
2. Andrew M., Paes B., Milner R., et al. Development of the human coagulation system in the full-term infant. Blood 1987, 70:165-172.
3. Andrew M., Vegh P., Johnston M., Bowker J., Ofosu F., Mitchell L. Maturation of the hemostatic system during childhood. Blood 1992, 80:1998-2005.
4. Andrew M., Paes B., Johnston M. Development of the hemostatic system in the neonate and young infant. Am J Pediatr Hematol Oncol 1990, 12:95-104.
5. Andrew M., Paes B., Milner R., et al. Development of the human coagulation system in the healthy premature infant. Blood 1988, 72:1651-1657.
6. Cook D.J., Guyatt G.H., Laupacis A., Sackett D.L. Rules of evidence and clinical recommendations on the use of antithrombotic agents. Chest 1992, 102(4 Suppl.):305S-311S.
7. Deutsch V.R., Olson T.A., Nagler A., Slavin S., Levine R.F., Eldor A. The response of cord blood megakaryocyte progenitors to IL-3, IL-6 and aplastic canine serum varies with gestational age. Br J Haematol 1995, 89:8-16.
8. Lupton B.A., Hill A., Whitfield M.F., Carter C.J., Wadsworth L.D., Roland E.H. Reduced platelet count as a risk factor for intraventricular hemorrhage. Am J Dis Child 1988, 142:1222-1224.
9. Austin N., Darlow B.A. Transfusion-associated fall in platelet count in very low birthweight infants. Aust Paediatr J 1988, 24:354-356.
10. Orchard P.J., Smith C.M., Woods W.G., Day D.L., Dehner L.P., Shapiro R. Treatment of haemangioendotheliomas with alpha interferon. Lancet 1989, 2(8662):565-567.
11. Samuels P., Main E.K., Tomaski A., Mennuti M.T., Gabbe S.G., Cines D.B. Abnormalities in platelet antiglobulin tests in preeclamptic mothers and their neonates. Am J Obstet Gynecol 1987, 157:109-113.
12. Monagle P., Barnes C., Ignjatovic V., et al. Developmental haemostasis. Impact for clinical haemostasis laboratories. Thromb Haemost 2006, 95:362-372.
13. Chan K.L., Summerhayes R.G., Ignjatovic V., Horton S.B., Monagle P.T. Reference values for kaolin-activated thromboelastography in healthy children. Anesth Analg 2007, 105:1610-1613.
14. Aballi A.J., De Lamerens S. Coagulation changes in the neonatal period and in early infancy. Pediatr Clin North Am 1962, 9:785-817.
15. Andrew M., Kelton J. Neonatal thrombocytopenia. Clin Perinatol 1984, 11:359-391.
16. Arad I.D., Alpan G., Sznajderman S.D., Eldor A. The mean platelet volume (MPV) in the neonatal period. Am J Perinatol 1986, 3:1-3.
17. Beverley D., Inwood M., Chance G., Schaus M., O'Keefe B. 'Normal' haemostasis parameters: a study in a well-defined inborn population of preterm infants. Early Hum Dev 1984, 9:249-257.
18. Castle V., Andrew M., Kelton J., Giron D., Johnston M., Carter C. Frequency and mechanism of neonatal thrombocytopenia. J Pediatr 1986, 108(5 Pt 1):749-755.
19. Gill F.M. Thrombocytopenia in the newborn. Semin Perinatol 1983, 7:201-212.
20. Joseph M.A., Adams D., Maragos J., Saving K.L. Flow cytometry of neonatal platelet RNA. J Pediatr Hematol Oncol 1996, 18:277-281.
21. Kipper S.L., Sieger L. Whole blood platelet volumes in newborn infants. J Pediatr 1982, 101:763-766.
22. Mehta P., Vasa R., Neumann L., Karpatkin M. Thrombocytopenia in the high-risk infant. J Pediatr 1980, 97:791-794.
23. Murray N.A., Roberts I.A. Circulating megakaryocytes and their progenitors (BFU-MK and CFU-MK) in term and pre-term neonates. Br J Haematol 1995, 89:41-46.
24. Murray N.A., Watts T.L., Roberts I.A. Endogenous thrombopoietin levels and effect of recombinant human thrombopoietin on megakaryocyte precursors in term and preterm babies. Pediatr Res 1998, 43:148-151.
25. Pearson H.A., McIntosh S. Neonatal thrombocytopenia. Clin Haematol 1978, 7:111-122.
26. Peterec S.M., Brennan S.A., Rinder H.M., Wnek J.L., Beardsley D.S. Reticulated platelet values in normal and thrombocytopenic neonates. J Pediatr 1996, 129:269-274.
27. Forestier F., Daffos F., Galacteros F., Bardakjian J., Rainaut M., Beuzard Y. Hematological values of 163 normal fetuses between 18 and 30 weeks of gestation. Pediatr Res 1986, 20:342-346.
28. Castle V., Coates G., Mitchell L.G., O'Brodovich H., Andrew M. The effect of hypoxia on platelet survival and site of sequestration in the newborn rabbit. Thromb Haemost 1988, 59:45-48.
29. Horgan M.J., Carrasco N.J., Risemberg H. The relationship of thrombocytopenia to the onset of persistent pulmonary hypertension of the newborn in the meconium aspiration syndrome. NY State J Med 1985, 85:245-247.
30. Rajasekhar D., Kestin A.S., Bednarek F.J., Ellis P.A., Barnard M.R., Michelson A.D. Neonatal platelets are less reactive than adult platelets to physiological agonists in whole blood. Thromb Haemost 1994, 72:957-963.
31. Hurtaud-Roux M., Hezard N., Lefranc V., et al. Quantification of the major integrins and P-selectin in neonatal platelets by flow cytometry. Thromb Haemost 2001, suppl. 284.
32. Jenkins C.S., Phillips D.R., Clemetson K.J., Meyer D., Larrieu M.J., Luscher E.F. Platelet membrane glycoproteins implicated in ristocetin-induced aggregation. Studies of the proteins on platelets from patients with Bernard-Soulier syndrome and von Willebrand's disease. J Clin Invest 1976, 57:112-124.
33. Gruel Y., Boizard B., Daffos F., Forestier F., Caen J., Wautier J.L. Determination of platelet antigens and glycoproteins in the human fetus. Blood 1986, 68:488-492.
34. Mull M.M., Hathaway W.E. Altered platelet function in newborns. Pediatr Res 1970, 4:229-237.
35. Whaun J.M., Smith G.R., Sochor V.A. Effect of prenatal drug administration on maternal and neonatal platelet aggregation and PF4 release. Haemostasis 1980, 9:226-237.
36. Andrew M., Castle V., Saigal S., Carter C., Kelton J.G. Clinical impact of neonatal thrombocytopenia. J Pediatr 1987, 110:457-464.
37. Andrew M., Schmidt B., Mitchell L., Paes B., Ofosu F. Thrombin generation in newborn plasma is critically dependent on the concentration of prothrombin. Thromb Haemost 1990, 63:27-30.
38. Feusner J.H. Normal and abnormal bleeding times in neonates and young children utilizing a fully standardized template technic. Am J Clin Pathol 1980, 74:73-77.
39. Harker L.A., Slichter S.J. The bleeding time as a screening test for evaluation of platelet function. N Engl J Med 1972, 287:155-159.
40. Katz J.A., Moake J.L., McPherson P.D., et al. Relationship between human development and disappearance of unusually large von Willebrand factor multimers from plasma. Blood 1989, 73:1851-1858.
41. Stuart M.J., Dusse J., Clark D.A., Walenga R.W. Differences in thromboxane production between neonatal and adult platelets in response to arachidonic acid and epinephrine. Pediatr Res 1984, 18:823-826.
42. Takahashi Y., Kawaguchi C., Hanesaka Y., et al. Plasma von Willebrand factor-cleaving protease is low in newborns. Thromb Haemost 2001, suppl. 285.
43. Ts'ao C.H., Green D., Schultz K. Function and ultrastructure of platelets of neonates: enhanced ristocetin aggregation of neonatal platelets. Br J Haematol 1976, 32:225-233.
44. Ucar T., Gurman C., Kemahli S. Platelet functions in preterm and term newborns. Thromb Haemost 2001, suppl. CD2298 (abstract).
45. Weinstein M.J., Blanchard R., Moake J.L., Vosburgh E., Moise K. Fetal and neonatal von Willebrand factor (vWF) is unusually large and similar to the vWF in patients with thrombotic thrombocytopenic purpura. Br J Haematol 1989, 72:68-72.
46. Widdershoven J., Kollee L., van Munster P., Bosman A.M., Monnens L. Biochemical vitamin K deficiency in early infancy: diagnostic limitation of conventional coagulation tests. Helv Paediatr Acta 1986, 41:195-201.
47. Corby D.G., O'Barr T.P. Decreased alpha-adrenergic receptors in newborn platelets: cause of abnormal response to epinephrine. Dev Pharmacol Ther 1981, 2:215-225.
48. Barradas M.A., Mikhailidis D.P., Imoedemhe D.A., Djahanbakhch O., Craft I.L., Dandona P. An investigation of maternal and neonatal platelet function. Biol Res Pregnancy Perinatol 1986, 7:60-65.
49. Gader A.M., Bahakim H., Jabbar F.A., Lambourne A.L., Gaafar T.H., Edrees Y.B. Dose-response aggregometry in maternal/neonatal platelets. Thromb Haemost 1988, 60:314-318.
50. Hicsonmez G., Prozorova-Zamani V. Platelet aggregation in neonates with hyperbilirubinaemia. Scand J Haematol 1980, 24:67-70.
51. Alebouyeh M., Lusher J.M., Ameri M.R., Evans R.K., Robinson A. The effect of 5-hydroxytryptamine and epinephrine on newborn platelets. Eur J Pediatr 1978, 128:163-168.
52. Niessen R.W., Lamping R.J., Peters M., Lamers W.H., Sturk A. Fetal and neonatal development of antithrombin III plasma activity and liver messenger RNA levels in sheep. Pediatr Res 1996, 39(4 Pt 1):685-691.
53. Sadowitz P.D., Walenga R.W., Clark D., Stuart M.J. Decreased plasma arachidonic acid binding capacity in neonates. Biol Neonate 1987, 51:305-311.
54. Landolfi R., De Cristofaro R., Ciabattoni G., et al. Placental-derived PGI2 inhibits cord blood platelet function. Haematologica 1988, 73:207-210.
55. Ahlsten G., Ewald U., Tuvemo T. Arachidonic acid-induced aggregation of platelets from human cord blood compared with platelets from adults. Biol Neonate 1985, 47:199-204.
56. Israels S.J., Gowen B., Gerrard J.M. Contractile activity of neonatal platelets. Pediatr Res 1987, 21:293-295.
57. Corby D.G., Zuck T.F. Newborn platelet dysfunction: a storage pool and release defect. Thromb Haemost 1976, 36:200-207.
58. Kosztolanyi G., Jobst K., Kellermayer M., Ludany A. ADP induced surface charge changes of adult and newborn platelets. Br J Haematol 1980, 46:257-262.
59. Stuart M.J. The neonatal platelet: evaluation of platelet malonyl dialdehyde formation as an indicator of prostaglandin synthesis. Br J Haematol 1978, 39:83-90.
60. Stuart M.J., Dusse J. In vitro comparison of the efficacy of cyclooxygenase inhibitors on the adult versus neonatal platelet. Biol Neonate 1985, 47:265-269.
61. Walenga R.W., Sunderji S., Stuart M.J. Formation of hydroxyeicosatetraenoic acids (HETE) in blood from adults versus neonates: reduced production of 12-HETE in cord blood. Pediatr Res 1988, 24:563-567.
62. Weiss H.J., Aledort L.M., Kochwa S. The effect of salicylates on the hemostatic properties of platelets in man. J Clin Invest 1968, 47:2169-2180.
63. Ambrus C.M., Weintrb D.H., Ambrus J.L. Studies on hyaine membrane disease.3. Thrapeutic trial of urokinase-activated huma plasmin. Pediatrics 1966, 38:231-243.
64. Aarts P.A., Bolhuis P.A., Sakariassen K.S., Heethaar R.M., Sixma J.J. Red blood cell size is important for adherence of blood platelets to artery subendothelium. Blood 1983, 62:214-217.
65. Jones C.R., McCabe R., Hamilton C.A., Reid J.L. Maternal and fetal platelet responses and adrenoceptor binding characteristics. Thromb Haemost 1985, 53:95-98.
66. Fernandez F., Goudable C., Sie P., et al. Low haematocrit and prolonged bleeding time in uraemic patients: effect of red cell transfusions. Br J Haematol 1985, 59:139-148.
67. Burgess C., Credland P., Kahir K. An evaluation of the usefulness of the PFA-100 device in 60 consecutive paediatric patients referred for investigation of potential haemostatic disorders. Thromb Haemost 2001, suppl. P378 (abstract).
68. Carcao M.D., Blanchette V.S., Dean J.A., et al. The Platelet Function Analyzer (PFA-100): a novel in-vitro system for evaluation of primary haemostasis in children. Br J Haematol 1998, 101:70-73.
69. Harrison P., Robinson M., Liesner R., et al. Performance of the PFA-100R as a potential screening tool for plately dysfunction. Thromb Haemost 2001, suppl. P378 (abstract).
70. Roschitz B., Sudi K., Kostenberger M. Shorter PFA-100 closure times in neonates than in adults is not caused by high red or white blood cell counts but depends on platelets and von Willebrand factor. Thromb Haemost 2001, suppl. P280 (abstract).
71. Slavec B., Benedik D. The platelet function analyzer (PFA-100): a novel system for evaluation of primary haemostasis. Thromb Haemost 2001, suppl. CD3310 (abstract).
72. Suarez C.R., Menendez C.E., Walenga J.M., Fareed J. Neonatal and maternal hemostasis: value of molecular markers in the assessment of hemostatic status. Semin Thromb Hemost 1984, 10:280-284.
73. Kaplan K.L., Owen J. Plasma levels of beta-thromboglobulin and platelet factor 4 as indices of platelet activation in vivo. Blood 1981, 57:199-202.
74. Stuart M., Wu J., Sunderji S., Ganley C. Effect of amniotic fluid on platelet thromboxane production. J Pediatr 1987, 110:289-292.
75. Tate D.Y., Carlton G.T., Johnson D., et al. Immune thrombocytopenia in severe neonatal infections. J Pediatr 1981, 98:449-453.
76. Podolsak B. Thrombopoiesis in newborn infants after exchange blood transfusion. Z Kinderheilkd 1973, 114:13-26.
77. Johnson D.H., Vinson A.M., Wirth F.H., et al. Management of hepatic hemangioendotheliomas of infancy by transarterial embolization: a report of two cases. Pediatrics 1984, 73:546-549.
78. Patrick C.H., Lazarchick J. The effect of bacteremia on automated platelet measurements in neonates. Am J Clin Pathol 1990, 93:391-394.
79. Monagle P., Hagstrom J. Developmental haemostasis. Fetal and neonatal physiology 2003, Elsevier, St Louis, 1435-1447. 3rd ed.
80. Ignjatovic V., Lai C., Summerhayes R., et al. Age-related differences in plasma proteins: how plasma proteins change from neonates to adults. PLoS One 2011, 6(2). e17213.
81. Bock S.R.C., et al. Antithrombin III and heparin cofactor II. Hemostasis and thrombosis: basic principles and clinical practice 2001, Lippincott Williams & Wilkins, Philadelphia, 321-334. 4th ed.
82. Witt I., Muller H. Phosphorus and hexose content of human foetal fibrinogen. Biochim Biophys Acta 1970, 221:402-404.
83. Hamulyak K., Nieuwenhuizen W., Devilee P.P., Hemker H.C. Re-evaluation of some properties of fibrinogen, purified from cord blood of normal newborns. Thromb Res 1983, 32:301-310.
84. Witt I., Muller H., Kunzer W. Evidence for the existence of foetal fibrinogen. Thromb Diath Haemorrh 1969, 22:101-109.
85. Miller B., Tosone S., Guzzetta N., Miller J., Brosius K. Fibrinogen in children undergoing cardiac surgery: is it effective?. Anesth Analg 2004, 99:1341-1346.
86. Dang C., Shin C., Bell W., Nagaswami C., Weisel J. Fibrinogen sialic acid residues are low affinity calcium binding sites that influence fibrin assembly. J Biol Chem 1989, 264:15104-15108.
87. Ignjatovic V., Ilhan A., Monagle P. Evidence for age-related differences in human fibrinogen. Blood Coagul Fibrinolysis 2011, 22:110-117.
88. Andrew M., Mitchell L., Berry L.R., Schmidt B., Hatton M.W. Fibrinogen has a rapid turnover in the healthy newborn lamb. Pediatr Res 1988, 23:249-252.
89. Manco-Johnson M., Spedale S., Peters Mea Identification of a unique form of protein C in the ovine fetus: developmentally linked transition to the adult form. Pediatr Res 1995, 37:685-691.
90. Monagle P., Ignjatovic V., Savoia H. Hemostasis in neonates and children: pitfalls and dilemmas. Blood Rev 2010, 24:63-68.
91. Taylor F.B., Kinasewitz G.T. The diagnosis and management of disseminated intravascular coagulation. Curr Hematol Rep 2002, 1:34-40.
92. Olson S.T., Bjork I., Shore J.D. Kinetic characterization of heparin-catalyzed and uncatalyzed inhibition of blood coagulation proteinases by antithrombin. Methods Enzymol 1993, 222:525-559.
93. Carrell R.W., Stein P.E., Fermi G., Wardell M.R. Biological implications of a 3 A structure of dimeric antithrombin. Structure 1994, 2:257-270.
94. Schreuder H.A., de Boer B., Dijkema R., et al. The intact and cleaved human antithrombin III complex as a model for serpin-proteinase interactions. Nat Struct Biol 1994, 1:48-54.
95. Levi M. All heparins are equal but some are more equal than others. J Thromb Haemost 2003, 1:884-885.
96. Chan A., Berry L., Paredes N., Parmar N. Isoform composition of antithrombin in a covalent antithrombin-heparin complex. Biochem Biophys Res Commun 2003, 309:986-991.
97. Picard V., Ersdal-Badju E., Bock S. Partial glycosylation of antithrombin III asparaginase-135 is caused by the serine in the third position of its N-glycosylation consensus sequence and is responsible for production of beta-antithrombin III isoform with enhanced heparin activity. Biochemistry 1995, 34:8433-8440.
98. Carlson T., Atencio A., Simon T. Comparison of the behaviour in vivo of two molecular forms of antithrombin III. Biochem J 1985, 225:557-564.
99. Witmer M., Hatton M. Antithrombin III-beta associates more rapidly than antithrombin III-alpha with uninjured and de-endothelialized aortic wall in vitro and in vivo. Arterioscler Thromb 1991, 11:530-539.
100. Turk B., Brieditis I., Bock S.C., Olson S.T., Bjork I. The oligosaccharide side chain on Asn-135 of alpha-antithrombin, absent in beta-antithrombin, decreases the heparin affinity of the inhibitor by affecting the heparin-induced conformational change. Biochemistry 1997, 36:6682-6691.
101. Schedin-Weiss S., Richard B., Hjelm R., Olson S.T. Antiangiogenic forms of antithrombin specifically bind to the anticoagulant heparin sequence. Biochemistry 2008, 47:13610-13619.
102. Adcock D.M., Fink L.M., Marlar R.A., Cavallo F., Zangari M. The hemostatic system and malignancy. Clin Lymphoma Myeloma 2008, 8:230-236.
103. Akl E.A., van Doormaal F.F., Barba M., et al. Parenteral anticoagulation for prolonging survival in patients with cancer who have no other indication for anticoagulation. Cochrane Database Syst Rev 2007, (3). CD006652.
104. Wojtukiewicz M.Z., Sierko E., Rak J. Contribution of the hemostatic system to angiogenesis in cancer. Semin Thromb Hemost 2004, 30:5-20.
105. Schmidt B., Gillie P., Mitchell L., Andrew M., Caco C., Roberts R. A placebo-controlled randomized trial of antithrombin therapy in neonatal respiratory distress syndrome. Am J Respir Crit Care Med 1998, 158:470-476.
106. Perlman M., Dvilansky A. Blood coagulation status of small-for-dates and postmature infants. Arch Dis Child 1975, 50:424-430.
107. Reverdiau-Moalic P., Delahousse B., Body G., Bardos P., Leroy J., Gruel Y. Evolution of blood coagulation activators and inhibitors in the healthy human fetus. Blood 1996, 88:900-906.
108. Salonvaara M., Riikonen P., Kekomaki R., et al. Effects of gestational age and prenatal and perinatal events on the coagulation status in premature infants. Arch Dis Child Fetal Neonatal Ed 2003, 88:F319-F323.
109. Mitsiakos G., Papaioannou G., Papadakis E., et al. Haemostatic profile of full-term, healthy, small for gestational age neonates. Thromb Res 2009, 124:288-291.
110. Boos J., Pollmann H., Dominick H.C. Vitamin K-dependent coagulation parameters during the first six days of life: incidence of PIVKA II in newborns. Pediatr Hematol Oncol 1989, 6:113-119.